"immune checkpoint" trang 9 - tải miễn phí từ tailieunhanh
Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: A systematic review and meta-analysis of clinical characteristics

Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: A systematic review and meta-analysis of clinical characteristics
17    7    1
Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
10    7    1
Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines

Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines
20    6    1
A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma

A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma
16    7    1
TALASUR trial: A single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma

TALASUR trial: A single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma
11    4    1
A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol

A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol
6    1    1
Low-dose nivolumab in advanced hepatocellular carcinoma

Low-dose nivolumab in advanced hepatocellular carcinoma
12    2    1
PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers

PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers
16    5    1
Notch signaling mutations increase intra-tumor chemokine expression and predict response to immunotherapy in colorectal cancer

Notch signaling mutations increase intra-tumor chemokine expression and predict response to immunotherapy in colorectal cancer
12    1    1
Phase II study of carboplatin/nab-paclitaxel/ atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial

Phase II study of carboplatin/nab-paclitaxel/ atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial
5    1    1
Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: An observational study

Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: An observational study
6    1    1
Impact of BMI on the survival outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis

Impact of BMI on the survival outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
14    1    1
Efficacy and safety analysis of TACE+Donafenib+Toripalimab versus TACE+Sorafenib in the treatment of unresectable hepatocellular carcinoma: A retrospective study

Efficacy and safety analysis of TACE+Donafenib+Toripalimab versus TACE+Sorafenib in the treatment of unresectable hepatocellular carcinoma: A retrospective study
11    8    1
The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma

The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma
11    1    1
Bladder metastasis with additional metastases in multiple other organs 4 years after radical nephrectomy for clear cell renal cell carcinoma: A case report and review of the literature

Bladder metastasis with additional metastases in multiple other organs 4 years after radical nephrectomy for clear cell renal cell carcinoma: A case report and review of the literature
6    15    1
Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: A case report

Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: A case report
6    18    1
Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: A case report

Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: A case report
6    25    1
Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2- low advanced or metastatic gastric cancer: A multicenter real-world study

Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2- low advanced or metastatic gastric cancer: A multicenter real-world study
8    1    1
Galectin 3 expression in regional lymph nodes and lymph node metastases of oral squamous cell carcinomas

Galectin 3 expression in regional lymph nodes and lymph node metastases of oral squamous cell carcinomas
10    59    0
Activated innate lymphoid cell populations accumulate in human tumour tissues

Activated innate lymphoid cell populations accumulate in human tumour tissues
10    68    1